HEMOGENYX PHARMACEUTICALS - HOPHF STOCK NEWS

Hemogenyx Pharmaceuticals has opened a new custom-engineered laboratory in the Mink Building, West Harlem, expanding its cell therapy capabilities. The facility features approx. 10,000 sq ft including two clean rooms for manufacturing its HEMO-CAR-T cell therapy aimed at treating acute myeloid leukemia. This move supports the company's growth in a prominent life sciences cluster near Columbia University. Hemogenyx, previously at SUNY Downstate, aims to simplify the commercialization of its product candidates.

Hemogenyx Pharmaceuticals announced that a recording of the investor webinar held on July 6, 2022, featuring CEO Dr. Vladislav Sandler, is now accessible on their YouTube channel. The company focuses on developing innovative treatments for blood and autoimmune diseases, leveraging technology to improve bone marrow transplantation outcomes. Hemogenyx emphasizes that their advancements could significantly benefit patients with conditions like leukemia, lymphoma, and severe autoimmune disorders.

Hemogenyx Pharmaceuticals plc has officially changed its registered office address to 6th Floor, 60 Gracechurch Street, London, EC3V 0HR, effective immediately. This relocation aims to enhance operational efficiency and accessibility. Hemogenyx continues to focus on developing innovative treatments for blood diseases, with its corporate governance structure remaining intact. The announcement reflects the company’s commitment to maintaining a professional presence in a key financial district in London.

Hemogenyx Pharmaceuticals has reported that all resolutions were passed at its Annual General Meeting on June 30, 2022. Key resolutions included the adoption of the 2021 Annual Report, approval of the Directors' Remuneration Policy, and reappointment of the Company’s auditor. Notably, the resolution for the Directors' Remuneration Policy had 84.7% votes in favor, while the Employee Incentive Plan garnered 97.9% approval. The total issued share capital as of June 28, 2022, was 979,749,321 shares. Full voting details are available via the National Storage Mechanism.

Hemogenyx Pharmaceuticals plc has announced a live investor webinar hosted by CEO Dr. Vladislav Sandler on July 6, 2022, at 16:00 BST. The session will provide an overview of the company's activities and future directions, along with a Q&A segment. Interested parties can register here. Hemogenyx focuses on developing treatments for blood and autoimmune diseases, aiming to enhance the accessibility of bone marrow transplantation for patients with severe conditions. The firm is based in London and operates subsidiaries in New York City.

Hemogenyx Pharmaceuticals has posted its Annual Report and Accounts for the year ending December 31, 2021, alongside the Notice of the Annual General Meeting (AGM) to shareholders. The AGM is scheduled for June 30, 2022, at 2:00 PM BST in London. Key documents, including the 2021 Equity Incentive Plan, are accessible on the company's website. Shareholders can find further details through provided contact information.

Hemogenyx Pharmaceuticals announces that Andrew Wright, the Financial Controller and Company Secretary, purchased 1,284,889 ordinary shares at a price of 1.44p each. Post-transaction, Wright holds a total of 4,000,000 shares, representing approximately 0.41% of the company's issued capital. This acquisition signals confidence in the company's future performance, with the transaction value totaling £18,502.40. The purchase occurred on May 27, 2022, on the London Stock Exchange.

Hemogenyx Pharmaceuticals plc has announced its participation in the Immuno-Oncology Summit Europe 2022, taking place from May 23-25, 2022, where Dr. Vladislav Sandler will present on anti-FLT3 CAR-T and bispecific antibody therapies for treating acute myeloid leukemia. This presentation aims to showcase the company’s product candidates, including CDX bispecific antibody and HEMO-CAR-T, highlighting their potential benefits for patients. The participation emphasizes the company's position in the biopharmaceutical sector and aims to enhance visibility among industry leaders.